



# The Evolving Role of Thiopurines in Inflammatory Bowel Disease

Saurabh Kapur, MD<sup>1</sup>  
Stephen B. Hanauer, MD<sup>2,\*</sup>

## Address

<sup>1</sup>Kansas University Medical Center, Kansas, KS, USA

<sup>2</sup>Northwestern University, Chicago, IL, USA

Email: shanauer@northwestern.edu

Published online: 21 November 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

This article is part of the Topical Collection on *Inflammatory Bowel Disease*

**Keywords** Inflammatory bowel disease · Thiopurines · Steroids · Immunogenicity · TPMT · Steroid-induced remission

## Abstract

*Purpose of review* With the advent of biologic therapies for the treatment of IBD, the roles of thiopurines have continued to evolve. This review will focus on recent advances in pharmacology and the safety and efficacy of thiopurines as maintenance therapies for steroid-induced remissions, post-surgical maintenance of remission, and as combination therapies to reduce immunogenicities of biologic agents.

*Recent findings* Due to pharmacogenetics of TPMT, thiopurine dosing is more effectively based on monitoring of thiopurine metabolites rather than weight-based dosing. Thiopurines continue to have a role as maintenance therapy after steroid-induced remissions and in combination with biologics to induce and maintain remission. Safety monitoring includes measurements of blood counts, liver chemistries, as well as dermatologic evaluations and protection from sun exposure.

*Summary* Thiopurines appear to be safe during pregnancies and while very uncommon, lymphomas (including hepatosplenic T cell lymphomas) remain a recognized risk, particularly in younger and older males.

## Introduction

Thiopurines (azathioprine, AZA; mercaptopurine, 6MP) have been used in the management of ulcerative colitis (UC) and Crohn's disease (CD) for multiple decades. However, with the advent of biologics and introduction of potent small molecules

(e.g., Janus kinase inhibitors), the role of thiopurines in the management of IBD needs to be redefined. In this review, we re-assess the current utilities and appropriate use of thiopurines in management of both UC and CD.

## Pharmacology

Thiopurine derivatives, AZA and 6MP, have no intrinsic activity; they undergo a series of multi-step enzymatic process to convert to active metabolites. AZA is a prodrug that is rapidly converted to 6MP in the liver and red blood cells [1, 2]. Further metabolism of 6MP occurs by three competitive enzymatic pathways: xanthine oxidase converts 6MP to 6-thiouric acid (thiourate), an inactive metabolite excreted by the kidneys; hypoxanthine phosphoribosyl transferase and a subsequent series of constitutive and inducible enzymes that convert 6MP to the metabolically active form 6-thioguanine nucleotides (6-TGN) which are phosphorylated and have antimetabolite and pro-apoptotic properties in bone marrow (primarily white blood cell and platelet lineages); and thiopurine S-methyltransferase (TPMT) that converts 6MP to 6-methyl-mercaptopurine (6MMP) [3], a less clinically effective metabolite that is associated with hepatic transaminitis. TPMT functional activity is determined by genetic polymorphisms such that 0.3% of the population is homozygous for absent TPMT activity, 10% of the population are heterozygotes with intermediate activity and the remainder of polymorphisms producing more TPMT enzymatic activity that divert 6MP metabolism to 6MMP [4]. Therefore, with similar doses of AZA or 6MP, low TPMT functional activity is associated with bone marrow suppression while high functional TPMT activity will divert 6MP metabolism away from 6TG and will be associated with elevated liver transaminases and less therapeutic impact on bone marrow-derived cells. While liver transaminitis does not lead to chronic liver disease, high concentrations of 6TG have been associated with veno-occlusive disease of the liver and nodular regenerative hyperplasia [5]. Therefore, to avoid bone marrow toxicity, it is recommended to check functional TPMT enzyme activity prior initiating to thiopurines and to utilize lower doses in patients with reduced functional activity [6, 7]. Most recently, a genetic polymorphism, NUDT15, that is more common in the Asian population, but also infrequently observed in Caucasians, has been recognized to be associated with an increased risk of myelosuppression [8••].

Trials in childhood leukemia utilized weight-based dosing of thiopurines that led to weight-based studies in IBD. Despite the observation that has correlated AZA and 6MP therapeutic effects (and bone marrow toxicity) with 6-TGN levels (e.g., in one study, 6-TGN levels  $> 292 \text{ pmol}/8 \times 10^8 \text{ RBCs}$  were associated with an 85.7% positive predictive value of clinical response) [9], ironically, most "guidelines" advocate weight-based dosing of 2.5 mg/kg for AZA and 1.5 mg/kg for 6MP [10]. In contrast, we and others have attempted to optimize thiopurine use by targeting a therapeutic range for 6-TGN and assessing 6-TGN and 6MMP metabolites in non-responding patients [11••].

## Induction therapy in Crohn's disease and ulcerative colitis

Numerous clinical trials as far back as the National Cooperative Crohn's Disease Study have failed to demonstrate an effect of thiopurines, as monotherapy, to induce clinical remissions in either CD or UC; usually attributed to their slow onset of action [12, 13]. In addition, a more recent randomized controlled trial (RCT) in early CD found AZA to be no more effective than placebo at inducing

sustained corticosteroid-free remission in CD [14], and results from a recent Cochrane meta-analysis of thirteen RCTs involving nearly 1200 patients showed no advantage for AZA or 6MP over placebo for induction of remission or clinical improvement in active CD [15]. There is limited, but similar data regarding lack of efficacy of thiopurines in inducing remissions in ulcerative colitis [16] [17]. As a result, thiopurines are not recommended as monotherapy for induction of remission in either CD or UC. Their primary role in induction therapy remains in combination with biologic agents (discussed in detail later).

## Maintenance therapy in Crohn's disease and ulcerative colitis

In contrast to the lack of efficacy of thiopurine monotherapy for induction remissions in IBD patients, the impact AZA and 6MP have on the maintenance of steroid-induced clinical remission has been well established in numerous controlled trials and meta-analyses. Thiopurines have demonstrated significant steroid-sparing effects as well as maintaining mucosal healing in CD [18]. In an observational study in CD patients on AZA monotherapy (mean duration 24.4 ± 13.7 months), complete mucosal healing was achieved in 70% of patients with ileitis and 54% of patients with colitis [19]. In addition, recent series have demonstrated evidence that thiopurines decrease surgical rates amongst CD patients [20]. In a cohort of pediatric patients with CD, use of AZA was associated with decreased surgical hazard rates (HR) of 0.51 (95% CI, 0.33–0.78), an effect that was more pronounced in patients for whom AZA was introduced earlier in their course of the disease [21]. Similarly, in UC, thiopurines have a more consistent impact as maintenance agents. In a meta-analysis of 30 studies involving 1600 patients, AZA/6MP showed a mean efficacy of 76% for maintenance of remission and an absolute risk reduction (ARR) of 23% (number needed to treat (NNT) of 5 compared with placebo in prevention of relapse) [22].

Another scenario where thiopurines have been utilized as maintenance therapy is for hospitalized patients with acute/severe UC following induction therapy with cyclosporine. Cyclosporine, a calcineurin inhibitor, has been shown to be efficacious as a rescue therapy after failure to respond to intravenous corticosteroids in hospitalized patients. Yet, while cyclosporine is an effective inductive agent, its use has not been similarly efficacious as a maintenance agent [23]. Thiopurines have been successfully used for maintaining remission after cyclosporine induction in these patients and thereby decreases colectomy rates in these complex patients [24].

Along the same line, there has been consistent evidence that thiopurines not only maintain clinical remission but also decrease longer-term IBD complications such as hospitalizations and surgeries, thus impacting on the “natural history” of UC and CD [25, 26]. Nevertheless, in Europe, therapeutic objectives in IBD are evolving such that de-escalation of therapy is an emerging goal. There have been relatively few studies assessing withdrawal of successful thiopurine maintenance therapy. An early trial demonstrated increasing relapse rates after withdrawal of azathioprine maintenance therapy in UC patients [27] and while a retrospective report of CD patients maintained on AZA suggested that, after 4 years of CD maintenance, azathioprine could be discontinued without loss of effectiveness [28], a prospective randomized trial by the same

group demonstrated that AZA withdrawal after 4 years of CD maintenance did lead to an increased risk of clinical relapse [29]. A recent meta-analysis by Boyapati et al. has also confirmed that withdrawal of AZA maintenance therapy in CD leads to an increased risk of clinical relapse in (32% vs 14%; RR 0.42) [30].

## Combination therapy with biologics

Despite consistent impact of thiopurines on the pharmacokinetic profiles of biologic agents (increased drug levels and reduced anti-drug antibodies) that was initially observed with infliximab in IBD, post hoc analyses of phase 3 studies enrolling patients with an “inadequate response” to AZA or 6MP failed to demonstrate a benefit for patients receiving concomitant thiopurines and infliximab [31, 32]. Similar results were noted in trials with adalimumab, certolizumab pegol, natalizumab, vedolizumab, and ustekinumab (see below). However, it must be noted that patients were not randomized according to ongoing immunomodulator therapy and the trials were not powered to demonstrate a difference between patients receiving concomitant immunomodulators.

In contrast, the pivotal SONIC (Study of Biologic and Immunomodulator Naïve Patients in Crohn’s Disease) trial prospectively compared infliximab monotherapy to azathioprine monotherapy and to combination therapy with infliximab and AZA (2.5 mg/kg). In the SONIC trial, enrolling immunosuppressive-naïve and bio-naïve patients with earlier Crohn’s disease, the results clearly showed superiority for combination therapy with steroid-free clinical remission rates of 30% on AZA monotherapy vs 56.8% receiving combination therapy ( $P < 0.0001$ ) vs. 44% for infliximab monotherapy ( $P = 0.02$ ) [33]. Similarly, the UC-SUCCESS trial demonstrated similar superiority with AZA/infliximab combination therapy in immunosuppressive- and biologic-naïve UC patients [34]. Whether results with combination therapy were due to medication synergy or increased drug levels of biologics was investigated in a post hoc analysis of SONIC by Colombel et al. that suggest that clinical outcomes were indistinguishable within groups having similar drug concentrations and point to the impact of AZA on infliximab pharmacokinetics and reduced clearance (including immunogenicity) as the mechanism of improved outcomes with combination therapy in IBD [35•]. The optimal dosing of thiopurines used in combination with IFX (and presumably other biologics) also remains to be established. In a cross-sectional analysis by Yarur et al., a 6-TGN of 125 pmol/ $8 \times 10^8$  red blood cells appeared adequate to achieve therapeutic levels of infliximab [36].

To date, there has been only one prospective study of adalimumab assessing monotherapy vs. combination therapy with a thiopurine in CD that demonstrated improvement in endoscopic outcomes (but not clinical remissions) with combination therapy [37]. However, while a meta-analysis of 7 studies assessing induction of remission ( $n \approx 1900$ ) suggested that adalimumab monotherapy was “mildly” inferior to combination therapy (OR = 0.78 (0.64–0.96),  $p = 0.02$ ) [38], there was no apparent impact on maintenance therapy and a recent post hoc analysis from a pediatric CD trial similarly failed to confirm a

benefit (or harm) with adalimumab combination therapy for induction or maintenance.

The efficacy of combination therapy with vedolizumab and thiopurines in IBD remains uncertain. Similar to trials with anti-TNF agents that enrolled proportions of patients not responding to thiopurines, post hoc analyses of the Gemini I and II trials showed no apparent clinical benefit of combination with immunosuppressive agents in CD and UC [39, 40]. Post hoc analyses of similarly designed phase 3 trials with ustekinumab did not identify better outcomes for patients on background immunosuppressive therapy [41]. Despite higher blood levels of vedolizumab and ustekinumab in patients receiving thiopurines, the overall rates of anti-drug antibodies were lower than those observed with infliximab suggesting that in the settings of biologics with longer half-lives and less inherent immunogenic properties, thiopurines may have less impact on pharmacokinetics and clinical outcomes [42].

Indeed, loss of response to biologic agents and anti-TNF agents, in particular, is a significant issue [43]. A significant proportion of patients lose response secondary to immunogenicity and the formation of anti-drug antibodies (ADAs) causes faster clearance and subtherapeutic drug levels [44]. Several recent studies have suggested that the addition of a thiopurine to patients who have developed anti-drug antibodies to anti-TNF biologics may reduce the presence of antibodies and allow improvement in the pharmacokinetics and clinical outcomes [45, 46, 47]. In a retrospective analysis by Strik et al., addition of thiopurine led to suppression of ADAs, increased drug levels, and recaptured clinical response in 77% of patients who had previously developed immunogenic failure to infliximab or adalimumab [48].

A common clinical question related to potential toxicities of thiopurines (see below) pertains to “how long” combination therapies with biologics and thiopurines should be continued. Separate randomized withdrawal trials of infliximab and AZA have assessed the impact of withdrawing one or the other agent. van Assche et al. found no benefits in clinical outcomes or mucosal healing of continuing thiopurines beyond 6 months, although higher infliximab drug levels and lower CRP levels were found in patients continuing on combination therapy beyond a year [49]. However, the previously mentioned Cochrane analysis did not demonstrate an increased risk of relapse in patients withdrawn from thiopurines during combination therapy with biologics [30]. In contrast, the STORI (infliximab diSconTinuation in CrOhn’s disease patients in stable Remission on combined therapy with Immunosuppressors) trial withdrew infliximab from patients receiving combination therapy with azathioprine and demonstrated gradual reductions in clinical remissions over time, particularly in patients who had not achieved “deep remissions.” [50] While debate is ongoing regarding the duration of combination therapy with biologics and thiopurines, ultimately, the use of therapeutic drug monitoring provides a rationale means of approaching a patient in a durable remission on combination therapy. Therapeutic biologic levels and low 6-TGN would justify stopping the thiopurine whereas “subtherapeutic” levels of a biologic and therapeutic 6-TGN would logically suggest stopping the biologic. Such an approach has yet to be evaluated in clinical trials.

## Special populations

### Pregnancy

AZA has been used during pregnancy in transplant and rheumatology patients for some time. In a retrospective study comparing outcomes of 187 IBD patients on thiopurines with non-exposed patients, unfavorable pregnancy-related outcomes defined as low birth weight, preterm deliver, congenital malformation, and death were 21.9% vs 31.8% ( $P = 0.01$ ) [51]. A meta-analysis of 7 studies with nearly 3000 patients revealed that thiopurines are not associated with low birth weight or congenital abnormalities, but may be associated with preterm delivery [52]. Similar results were confirmed in a prospective study from the Netherlands in which 309 IBD patients (216 CD and 85 UC) were followed during 311 pregnancies. Thiopurines were used during 108 pregnancies and the authors found no difference in pregnancy outcomes or infant health at 1 year between the study and control group [53].

Thiopurines are now generally considered safe in pregnant IBD patients [43]. A 2011 survey of gastroenterologists with > 82,000 IBD patients showed that greater than 90% recommended continuous thiopurine treatment [54, 55].

### Postoperative Crohn's disease

More than half of patients with CD will undergo at least one intestinal resection during the course of their disease and postoperative recurrence (POR) is common [56]. Thiopurines alone or in combination with other agents (imidazoles or anti-TNF agents) are often recommended for reducing the risk of POR [57, 58]. In a prospective randomized controlled trial, compared with placebo, 6MP was shown to be more effective at preventing clinical and endoscopic recurrences at 2 years (50% vs 77% and 43% vs 64% respectively  $P < 0.05$ ) [59]. In a retrospective analysis of 326 patients, Papay et al. showed significant reduction in re-operation rate with long-term AZA use (> 36 months) as compared with the control groups (< 36 months and no treatment) [60]. A meta-analysis of four randomized clinical trials with total of 433 patients concluded that thiopurines were more effective than placebo for preventing endoscopic recurrence of Rutgeert's i2-4 lesions (mean difference, 23%; 95% CI, 9-37%;  $P = 0.0016$ ; NNT = 4) at 1 year after surgery [61].

### Thiopurines and risk prevention of colorectal cancer

Patients with IBD are at increased risk of colorectal cancer (CRC); this risk is related to duration and the extent of colonic involvement [62]. Since chronic inflammation is the key driver for increased risk [63] of colonic neoplasia in IBD, the anti-inflammatory properties of thiopurines should be protective although evidence to that effect remains inconclusive. In a retrospective population-based study from the Netherlands involving nearly 2500 patients, the use of thiopurines was associated with a decreased risk of neoplasia (HR 0.10 (95% CI 0.01 to 0.75)) [64]. While a meta-analysis performed in 2014 did not find a protective benefit of thiopurines against colonic neoplasia [65], a more recent systematic review and meta-analysis of 95,000 patients supported a protective effect of thiopurines against CRC in IBD [66].

## Thiopurines in patients with a previous history of cancer

The use of thiopurines in patients with a previous history of cancer remains controversial due to insufficient data. While a previous study suggested delaying treatment with thiopurines for 3 to 5 years after a cancer diagnosis [67], a subsequent meta-analysis of 16 studies with more than 11,000 patients has shown no difference in cancer recurrence between non-exposed and exposed patients on immunomodulators [68].

## Uninsured/underinsured populations

A substantial proportion of the US population remain uninsured or underinsured. IBD has relatively low prevalence but a high-cost disease and drug costs are a significant proportion of that expenditure [69, 70]. Biologics which are considered the most effective therapy for moderate to severe IBD remain expensive [71]. Immunomodulators, including thiopurines, can provide a cost-effective treatment strategy in this population [72].

## Side effects

Toxicities from thiopurines, including intolerance and allergy, can be dose-dependent or idiosyncratic [73] and account for the observation that approximately 25% of the exposed patients develop an adverse reaction and 17% discontinue therapy due to adverse events [74].

The most frequent intolerance to thiopurines is nausea, experienced by up to 10% of patients, with females and CD patients at most risk [74]. Other common intolerant side effects include arthralgias, malaise, and flu-like illnesses [75]. Approximately 60–70% of patients who develop intolerance to AZA will tolerate a switch to 6MP, but not vice versa [3].

In contrast, acute pancreatitis is an allergic side effect that can occur in up to 7% of patients started on thiopurines with almost all cases presenting in first 2 to 3 weeks after initiating therapy. With immediate drug withdrawal, most cases are mild and resolve spontaneously [76]. In this setting, pancreatitis or other allergic reactions such as rash, fever, or arthritis, re-challenge or substitution between AZA and 6MP typically induce similar toxicities and can include a septic shock-like syndrome. In contrast, a few small case series have demonstrated that "cautious" challenge or substitution of thioguanine can be successfully tolerated [77].

## Dose-dependent reactions

### *Myelosuppression*

The cumulative incidence of bone marrow suppression from thiopurines ranges from 5 to 7% [75] and is related to TPMT functional activity (see above). Leukopenia is the most common presentation, although thrombocytopenia or pancytopenia can develop [78]. Bone marrow suppression can develop over weeks or arise during long-term therapy [79]. High 6-TGN levels have been related to leukopenia, related to AZA or 6MP [80], justifying recommendations for measuring functional TPMT activity prior to initiating therapy, particularly if introduced in a milligram per kilogram

strategy. Reduced dosing (e.g., 50% reduction) is advocated for intermediate functional TPMT activity (approximately 15% of the population) and patients with homozygous low activity (approximately 1/300 individuals) should either avoid AZA/6MP in favor of 6TG or be initiated at 10% of standard dosing with extremely close monitoring of leukocyte counts. Other correlates with 6-TGN levels include leukopenia, itself, as well as elevated erythrocyte mean corpuscular volume [81]. Common recommendations for therapeutic drug monitoring include measuring complete blood counts (CBC) every 1 to 2 weeks after initiating therapy to avoid acute bone marrow suppression and then subsequently every 3 months to avoid the risk of late-onset myelosuppression [79]. In Asian populations, and less commonly in Caucasians, genome-wide studies have implicated NUDT15 variants were associated with increased risk of thiopurine-associated myelosuppression, irrespective of dose or the TPMT levels [8••, 82].

### *Immunosuppression*

---

Even in the absence of neutropenia, viral, bacterial, parasitic, and fungal infections have been associated with the use of thiopurines, with a particular increased risk of viral infections [83]. Risk factors for infections include advanced age, malnutrition, other comorbid conditions (diabetes, chronic lung disease, etc.), and concomitant use of other immunosuppressive therapies (including corticosteroids) [84]. Kirchesner et al. evaluated serious infections (requiring hospitalization) in a large French population data base of 200,000 patients. The rate of serious infections was 0.8% (1 in 125) in unexposed as compared with 1.1% (1 in 91) in patients with thiopurine monotherapy. Incidence rates were higher (2.2%) for patients on combination therapy with biologics, particularly in the subgroup patients older than 65 [85]. Thus, it is recommended that patients about to initiate thiopurine or other immunosuppressive therapies (including biologics) receive age-appropriate vaccinations (including influenza, pneumococcus, zoster, hepatitis B, and human papilloma virus) [86].

### *Malignancies*

---

Lymphomas are the most relevant neoplastic concern associated with thiopurines that usually occur in individuals previously exposed to Epstein-Barr virus [87]. In a recent nationwide cohort study based on the French National Health Insurance data bases of 189,000 IBD patients followed for a median of 6.7 years, the absolute risk of lymphoma was low (336 cases). A total of 220 cases were in patients without thiopurine exposure (incidence rate [IR] per 1000 person-years, 0.26; 95% CI, 0.23–0.29) vs the 70 cases in patients exposed to thiopurine monotherapy (IR, 0.54; 95% CI, 0.41–0.67) with an adjusted hazard ratio (aHR) of 2.60 (95% CI, 1.96–3.44;  $P < .001$ ). The risk was also higher in individuals on combination therapy with anti-TNF agents (aHR, 6.11 (95% CI, 3.46–10.8;  $P < .001$ )) [88••]. A meta-analysis of 18 studies demonstrated that the risk of lymphoma was proportional to duration of therapy, becoming significantly increased after 1 year of use but reverting to baseline after discontinuation

of therapy. Subgroup analysis identified males having had approximately twice the relative risk (RR) compared with females, with patients younger than 30 years having the highest relative risk (standardized incidence ratio = 7) and younger men having the highest risk (approximately 9-fold). While the RR approximated 6-fold, the magnitude in the absolute term remains low with the highest RR being in patients older than 50 years (1:354 cases per patient-year, with a RR of 4.78) [89].

Hepatosplenic T cell lymphoma (HTCL) is the least common, highly aggressive, and most lethal lymphoma subtype associated with thiopurine therapy linked to AZA/6MP monotherapy or in combination therapy with anti-TNF agents. This rare, nearly always fatal lymphomas occur primarily in young males under the age of 35 years after a minimum of 2 years [90]. However, it is important to point out recent case reports of HTCL occurring with use of anti-TNF combination therapy with methotrexate, in older patients (> 65) and in females [91]. Another rare, uniformly fatal syndrome, hemophagocytic lymphohistiocytosis (HLH), is a multisystem inflammatory response in which the mononuclear phagocyte system is activated [92]. The risk of this syndrome and other B cell lymphomas is particularly high in individuals who develop a primary Epstein-Barr virus (EBV) infection while on thiopurines [93]. A frequently implied but not yet uniformly recommended strategy is to check EBV status before starting thiopurines and to avoid using these drugs in patient who are at risk of acquiring a primary EBV infection [94].

#### *Skin cancer*

Thiopurines are known to increase the risk of non-melanotic skin cancer (NMSC). In a study of almost 13,000 IBD patients, of which nearly 3000 patients were on thiopurines, the risk of NMSC was higher in exposed as compared with the unexposed with aHR of 2.1 ( $P < 0.0001$ ) [95]. Though data remain conflicting, in this particular study, the risk decreased to the baseline levels after stopping thiopurines (aHR 0.7 ( $P = 0.07$ )). The study also associated the risk linked to duration of exposure with a significant increase in risk after 2 years of continuous thiopurine exposure. No association was found between melanomas and thiopurine use [95].

In "light" of these studies, it is recommended that patients receiving thiopurines should minimize direct sun exposure, use sun block, and have regular dermatological screening [96•].

#### **Best practice**

In this era of personalized medicine, thiopurines still have an important, but evolving, role in the management of IBD. They remain advocated by GI societies in the USA and abroad for maintenance therapy after steroid induction for both UC [97•, 98, 99] and CD [57•, 100–103]. Thiopurines have a slow onset of action and are not recommended as single agents for induction of remission in either UC or CD [102, 103]. Pretreatment TPMT enzyme testing and weight-based dosing are endorsed; however, response is best correlated with 6-TGN levels in RBCs [11••]. Combination therapies with immunomodulators and anti-TNF biologics (primarily IFX) are more effective than either thiopurine or

biologic monotherapy in both CD [33] and UC[34] where, based on post hoc analysis, the increased efficacy was associated with reduced immunogenicity and increased drug levels [35•]. It remains to be determined if this advantage is maintained with other anti-TNFs [104, 105] or newer biologic agents.

Close laboratory monitoring for hematologic and hepatic toxicities is recommended. There is increased, but uncommon, risk of lymphomas and other rare hematological malignancies, and the risk increases with age and is higher in patients on combination therapy. Increased risks for non-melanoma skin cancers with thiopurines warrant sun protection and regular dermatologic examinations. Thiopurines are also associated with an increased risk of viral and other opportunistic infections; thus, expansion age-appropriate vaccinations are recommended before initiating and during maintenance therapy with thiopurines and other immunosuppressive therapies.

Thiopurines may provide cost-effective approaches to treatment of IBD (e.g., compared with biologics) but should demand similar monitoring of clinical and endoscopic endpoints currently advocated in “treat to target” strategies for CD and UC [106, 107].

## Compliance with Ethical Standards

### Conflict of Interest

Saurabh Kapur declares that he has no conflict of interest. Stephen B. Hanauer declares that he has no conflict of interest.

### Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

## References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Hindorf U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. *Gut*. 2006;55:1423–31.
2. Eklund BI, Moberg M, Bergquist J, Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. *Mol Pharmacol*. 2006;70:747–54.
3. Amin J, Huang B, Yoon J, Shih DQ. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. *Inflamm Bowel Dis*. 2015;21:445–52.
4. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. *Am J Hum Genet*. 1980;32:651–62.
5. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. *Gastroenterology*. 2003;125:298–303.
6. Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. *Ther Drug Monit*. 2004;26:311–8.
7. Gardiner SJ, Geary RB, Begg EJ, et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. *Clin Gastroenterol Hepatol*. 2008;6:654–60 quiz 604.

- 8.●● Walker GJ, Harrison JW, Heap GA, et al. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease. *JAMA*. 2019;321:773–8.
- Identification of a new genetic variant in thiopurine metabolism associated with an increased risk of myelosuppression with thiopurine use.
9. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2004;2:410–7.
10. Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, et al. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. *Aliment Pharmacol Ther*. 2014;39:163–75.
- 11.●● Yarur AJ, Gondal B, Hirsch A, et al. Higher thioguanine nucleotide metabolite levels are associated with better long-term outcomes in patients with inflammatory bowel diseases. *J Clin Gastroenterol*. 2018;52:537–44
- Updated confirmation of thioguanine metabolite levels as predictor of response than weight-based dosing.
12. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. *N Engl J Med*. 1980;302:981–7.
13. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group *Gastroenterology*. 1999;117:527–35.
14. Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. *Gastroenterology*. 2013;145:766–74.e1.
15. Chande N, Townsend CM, Parker CE, et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2016;10:Cd000545.
16. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. *Br Med J*. 1974;4:627–30.
17. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol*. 2011;106:630–42.
18. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2013:Cd000545.
19. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. *Gastrointest Endosc*. 1999;50:667–71.
20. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. *Gut*. 2005;54:237–41.
21. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. *Gastroenterology*. 2008;135:1106–13.
22. Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. *Aliment Pharmacol Ther*. 2009;30:126–37.
23. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. *Am J Gastroenterol*. 1999;94:1587–92.
24. Miyake N, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, et al. Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis. *World J Gastroenterol*. 2015;21:254–61.
25. Singh H, Bernstein CN. Sorting through the risks and benefits of thiopurine therapy for inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2019.
- 26.● Eriksson C, Rundquist S, Cao Y, et al. Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. *Gut*. 2019;68:623–32
- Additional support for efficacy of thiopurines to prevent long-term complications of ulcerative colitis.
27. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. *BMJ*. 1992;305:20–2.
28. Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. *Lancet*. 1996;347:215–9.
29. Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. *Clin Gastroenterol Hepatol*. 2009;7:80–5.
30. Boyapati RK, Torres J, Palmela C, et al. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. *Cochrane Database Syst Rev*. 2018;5:Cd012540.
31. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. *Gut*. 2007;56:1232–9.
32. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. *N Engl J Med*. 2004;350:876–85.
33. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med*. 2010;362:1383–95.
34. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. *Gastroenterology*. 2014;146:392–400.e3.
- 35.● Colombel JF, Adedokun OJ, Gasink C, et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and

- efficacy: a post hoc analysis. *Clin Gastroenterol Hepatol*. 2019;17(8):1525–3.
- Post hoc analysis of SONIC study suggesting that azathioprine may be efficacious in combination with infliximab by raising blood levels of the biologic in contrast to mechanistic synergy.
36. Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. *Clin Gastroenterol Hepatol*. 2015;13:1118–24.e3.
  37. Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial. *J Crohns Colitis*. 2016;10:1259–66.
  38. Kopylov U, Al-Taweel T, Yaghoobi M, et al. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis. *J Crohns Colitis*. 2014;8:1632–41.
  39. Feagan BG, Chande N, MacDonald JK. Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from Cochrane reviews. *Inflamm Bowel Dis*. 2013;19:2031–40.
  40. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med*. 2013;369:711–21.
  41. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med*. 2016;375:1946–60.
  42. Al-Bawardy B, Ramos GP, Willrich MAV, et al. Vedolizumab drug level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease. *Inflamm Bowel Dis*. 2019;25(3):580–6.
  43. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. *Am J Gastroenterol*. 2011;106:685–98.
  44. Baert F, Noman M, Vermeire S, van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med*. 2003;348:601–8.
  45. • Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. *Aliment Pharmacol Ther*. 2017;45:276–8.
- Additional evidence that thiopurines reduce immunogenicity to biologic therapies.
46. Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2013;11:444–7.
  47. van Schaik T, Maljaars JP, Roopram RK, Verwey MH, Ipenburg N, Hardwick JC, et al. Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD. *Inflamm Bowel Dis*. 2014;20:2292–8.
  48. Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D'Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. 2017;45:1128–34.
  49. van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. *Gastroenterology*. 2008;134:1861–8.
  50. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. *Gastroenterology*. 2012;142:63–70 e5 quiz e31.
  51. Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. *Am J Gastroenterol*. 2013;108:433–40.
  52. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2013;19:15–22.
  53. Kanis SL, de Lima-Karagiannis A, de Boer NKH, et al. Use of thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study. *Clin Gastroenterol Hepatol*. 2017;15:1232–1241.e1.
  54. Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP. The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. *Aliment Pharmacol Ther*. 2011;33:707–13.
  55. • Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. *Gastroenterology*. 2016;150:734–757.e.
- Review of safety of thiopurine use in pregnancy.
56. Orlando A, Mocciano F, Renna S, Scimeca D, Rispo A, Lia Scribano M, et al. Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multi-center cohort. *J Crohns Colitis*. 2014;8:1217–21.
  57. • Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. *Am J Gastroenterol*. 2018;113:481–51.
- Current US Society guideline on treatment of Crohn's disease including role of thiopurines.
58. Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3rd European evidence-based consensus on the diagnosis and management of

- Crohn's disease 2016: part 2: surgical management and special situations. *J Crohns Colitis*. 2017;11:135–49.
59. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. *Gastroenterology*. 2004;127:723–9.
60. Papay P, Reinisch W, Ho E, Gratzner C, Lissner D, Herkner H, et al. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. *Am J Gastroenterol*. 2010;105:1158–64.
61. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. *Am J Gastroenterol*. 2009;104:2089–96.
62. Jewel Samadder N, Valentine JF, Guthery S, Singh H, Bernstein CN, Wan Y, et al. Colorectal cancer in inflammatory bowel diseases: a population-based study in Utah. *Dig Dis Sci*. 2017;62:2126–32.
63. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. *Gastroenterology*. 2004;126:451–9.
64. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden G, Siersema PD, Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. *Gut*. 2012;61:235–40.
65. Jess T, Lopez A, Andersson M, et al. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. *Clin Gastroenterol Hepatol*. 2014;12:1793–1800.e1.
66. Zhu Z, Mei Z, Guo Y, Wang G, Wu T, Cui X, et al. Reduced risk of inflammatory bowel disease-associated colorectal neoplasia with use of thiopurines: a systematic review and meta-analysis. *J Crohns Colitis*. 2018;12:546–58.
67. Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. *Gut*. 2013;62:1523–8.
68. Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. *Gastroenterology*. 2016;151:97–109.e4.
69. Mehta F. Report: economic implications of inflammatory bowel disease and its management. *Am J Manag Care*. 2016;22:s51–60.
70. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. *Gastroenterology*. 2008;135:1907–13.
71. Wu N, Lee YC, Shah N, et al. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. *Clin Ther*. 2014;36:1231–41 1241.e1–3.
72. Sewell JL, Velayos FS. Systematic review: the role of race and socioeconomic factors on IBD healthcare delivery and effectiveness. *Inflamm Bowel Dis*. 2013;19:627–43.
73. Yao Q, Altman RD. Thiopurine methyltransferase measurement may not predict azathioprine-associated non-myelotoxicity. *Clin Exp Rheumatol*. 2013;31:156.
74. Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. *Inflamm Bowel Dis*. 2013;19:1404–10.
75. Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, et al. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss inflammatory bowel disease cohort. *Eur J Gastroenterol Hepatol*. 2018;30:612–20.
76. Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehle S, et al. Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases—a prospective study on incidence and severity. *J Crohns Colitis*. 2016;10:61–8.
77. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. *Am J Gastroenterol*. 2003;98:1058–63.
78. Broekman M, Coenen MJH, Wanten GJ, et al. Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype. *Aliment Pharmacol Ther*. 2017;46:953–63.
79. de Jong DJ, Goulet M, Naber TH. Side effects of azathioprine in patients with Crohn's disease. *Eur J Gastroenterol Hepatol*. 2004;16:207–12.
80. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. *Am J Gastroenterol*. 2008;103:1783–800.
81. Kopylov U, Battat R, Benmassaoud A, et al. Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD. *Dig Dis Sci*. 2015;60:478–84.
82. Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. *Nat Genet*. 2016;48:367–73.
83. Vogelín M, Biedermann L, Frei P, et al. The impact of azathioprine-associated lymphopenia on the onset of opportunistic infections in patients with inflammatory bowel disease. *PLoS One*. 2016;11:e0155218.
84. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. *Arthritis Rheum*. 2002;46:2294–300.
85. Kirchgessner J, Lemaitre M, Carrat F, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. *Gastroenterology*. 2018;155:337–346.e10.
86. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, de Munter P, D'Haens G, et al. European evidence-based

- consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis*. 2009;3:47–91.
87. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. *Gastroenterology*. 2002;122:72–7.
  - 88.●● Lemaitre M, Kirchgessner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. *JAMA*. 2017;318:1679–8.
- Large data base demonstrating small but significant risk of lymphoma with thiopurines alone or in combination with TNF inhibitors.
89. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. *Clin Gastroenterol Hepatol*. 2015;13:847–58.e4 quiz e48–50.
  90. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2011;9:36–4.
- e1.
91. Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED. Hepatosplenic T-cell lymphoma in patients receiving TNF-alpha inhibitor therapy: expanding the groups at risk. *Eur J Gastroenterol Hepatol*. 2011;23:1150–6.
  92. Virdis F, Tacci S, Messina F, et al. Hemophagocytic lymphohistiocytosis caused by primary Epstein-Barr virus in patient with Crohn's disease. *World J Gastrointest Surg*. 2013;5:306–8.
  93. de Francisco R, Castano-Garcia A, Martinez-Gonzalez S, et al. Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. 2018;48:723–30.
  94. Gordon J, Ramaswami A, Beuttler M, et al. EBV status and thiopurine use in pediatric IBD. *J Pediatr Gastroenterol Nutr*. 2016;62:711–4.
  95. Abbas AM, Almukhtar RM, Loftus EV Jr, et al. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. *Am J Gastroenterol*. 2014;109:1781–93.
  - 96.● Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG clinical guideline: preventive care in inflammatory bowel disease. *Am J Gastroenterol*. 2017;112:241–5.
- Relevance of preventive health maintenance for IBD patients receiving immune suppression.
- 97.● Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol*. 2019;114:384–41.
- Current US Society guideline on management of ulcerative colitis including role of thiopurines.
98. Harbord M, Eliakim R, Bettenworth D, Kamirris K, Katsanos K, Kopylov U, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management. *J Crohns Colitis*. 2017;11:769–84.
  99. Dassopoulos T, Cohen RD, Scherl EJ, et al. Ulcerative colitis care pathway. *Gastroenterology*. 2015;149:238–45.
  100. Gomollon F, Dignass A, Annesse V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. *J Crohns Colitis*. 2017;11:3–25.
  101. Sandborn WJ. Crohn's disease evaluation and treatment: clinical decision tool. *Gastroenterology*. 2014;147:702–5.
  102. Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving considerations for thiopurine therapy for inflammatory bowel diseases—a clinical practice update: commentary. *Gastroenterology*. 2019;156:36–42.
  103. Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. *Gastroenterology*. 2013;145:1464–78 e1–5.
  104. Hyams JS, Dubinsky M, Rosh J, et al. The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis. *Aliment Pharmacol Ther*. 2019;49:155–64.
  105. Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, et al. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. *Aliment Pharmacol Ther*. 2017;45:50–62.
  106. Khanna R, Jairath V, Feagan BG. The evolution of treatment paradigms in Crohn's disease: beyond better drugs. *Gastroenterol Clin N Am*. 2017;46:661–77.
  107. Ungaro R, Colombel JF, Lisssoos T, Peyrin-Biroulet L. A treat-to-target update in ulcerative colitis: a systematic review. *Am J Gastroenterol*. 2019 Jun;114(6):874–83.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.